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NATURAL HISTORY OF TRICUSPID REGURGITANT JET VELOCITY AND
A NEW ASSOCIATION WITH PROTEINURIA IN CHILDREN WITH SICKLE
CELL DISEASE. Suzanne J. Forrest, Judith L. Carbonella, Farzana D. Pashankar,
Section of Hematology and Oncology, Department of Pediatrics, Yale University, School
of Medicine, New Haven, CT.
Given the morbidity and mortality associated with pulmonary hypertension and
progressive renal failure in sickle cell disease, recognition of both organ dysfunctions
during childhood should allow for improved management of patients and early treatment
for both. The definitive diagnosis of pulmonary hypertension is made on cardiac
catheterization, however measurement of tricuspid regurgitant jet velocity (TRV) on
echocardiogram can be used to estimate pulmonary artery systolic pressures and can be
used as a screening modality for pulmonary hypertension. Pulmonary hypertension is
defined as TRV ! 2.5 m/sec and occurs in 16-30% of children with sickle cell disease on
screening echocardiograms. Two studies were conducted on a cohort of children from
the sickle cell program at Yale New Haven Children’s Hospital. The first study was
conducted to determine the longitudinal natural history of TRV in untreated children with
sickle cell disease (N=100 patients). A detailed retrospective chart review was conducted
on all sickle cell patients screened with echocardiograms from June 2005 to November
2012. Patients aged 6-21 years were included, 87 with HbSS and 13 with S!°
thalassemia. At baseline, 67% of patients (N=67) had normal TRV <2.5 m/sec and 33%
of patients (N=33) had elevated TRV !2.5 m/sec on screening echocardiogram. Follow
up echocardiograms were available for 82% of patients (82 of 100), and the median
follow up time was 3.59 years. On follow up, 61.40% (N=35) of patients with baseline
normal TRV continued to have normal TRV on all subsequent echocardiograms, whereas
38.60% (N=22) of patients had at least 1 echocardiogram with an elevated TRV. Risk
!

factors associated with TRV conversion were baseline low O2 saturation, low
hemoglobin and high reticulocyte count (all P <0.05). On follow up, 32% (N=25) of
patients with elevated TRV at baseline continued to have elevated TRV on all subsequent
echocardiograms, whereas 68% (N=17) of patients had at least 1 echocardiogram with
normal TRV without intervention. Risk factors associated with persistent TRV elevation
were baseline elevated TRV, low hemoglobin, and high white blood count (all P <0.05).
Three of the 100 patients died during the follow up period, one with elevated TRV. A
second study was conducted to determine whether elevated TRV was associated with
proteinuria in children with sickle cell disease (N=85 patients). A detailed chart review
was conducted on sickle cell patients screened with both echocardiograms and urinalysis
from June 2005 to July 2010. Longitudinal data from subsequent echocardiograms and
urine analyses were also collected. On initial echocardiograms, 32.9% (N=28) had an
elevated TRV ! 2.5 m/sec. At initial screening 7.14% (N=2) of these patients with
elevated TRV had proteinuria, compared to only 1.75% (N=1) without elevated TRV
(P=0.25). On follow up, 19.08% of repeat urinalysis showed proteinuria in patients with
elevated baseline TRV compared to 12.35% in patients with normal baseline TRV
(P=0.04). Our first study revealed that patients with elevated TRV should be followed
longitudinally prior to initiating treatment, as many patients will have normalization of
TRV without intervention. The first study also showed that patients with high hemolytic
rate as evidenced by low hemoglobin and high reticulocyte count are at high risk of TRV
conversion and should be monitored closely. Our second study found a new association
between elevated TRV and proteinuria in children with sickle cell disease followed
longitudinally.
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INTRODUCTION

Overview of Sickle Cell Disease
Approximately 90,000 people live with sickle cell disease in the United States with
an estimated 1 in 2,500 children is born with a form of sickle cell disease each year (1, 2).
Sickle cell hemoglobinopathy is a heterogeneous set of diseases characterized by the
presence of at least one hemoglobin ! globin gene affected by the sickle mutation (2).
Hemoglobin, the protein within a red blood cell that carries oxygen, is composed of four
globin chains, two " globin and two ! globin chains. Sickle cell disease occurs when an
offspring inherits either two sickle ! globin genes or one sickle ! globin gene in
combination with another ! globin chain mutation (2, 3). Approximately 60-65% of
sickle cell disease patients are homozygous for the sickle mutation and have HbSS
disease. The most common compound heterozygote state, affecting approximately 2530% of patients with sickle cell disease is sickle hemoglobin-C disease. Another form of
sickle cell disease, representing approximately 5-10% of patients with
hemoglobinopathies, is caused by coinheritance of a ! thalassemia mutation with the
sickle mutation which results in S!° thalassemia (2). Patients with HbSS disease and S!°
thalassemia, who completely lack normal ! globin production, are generally more
severely affected than patients with SC disease (3). For the purposes of this thesis, sickle
cell disease refers to patients with HbSS and S!° thalassemia.
Sickle cell disease can affect any organ in the body. The principal clinical
manifestations of patients with sickle cell disease are hemolytic anemia, episodes of
vaso-occlusion, and increased susceptibility to infection (4, 5). These pathologic
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processes are a result of deoxygenation of the hemoglobin S molecule, which forms an
intracellular polymer aggregate, ultimately causing the red cell to sickle (6). The sickle
cell mutation, a single nucleotide change in the coding region of the ! globin gene,
results in an amino acid change from glutamic acid to valine. The amino acid change
from a hydrophilic glutamic acid to a hydrophobic valine residue is what causes protein
polymerization in a deoxygenated state (2). The sickled red blood cells can obstruct the
microvasculature and, unlike normal red blood cells are more likely to adhere to the
vascular endothelium (7, 8). Both of these processes contribute to and ultimately cause
vaso-occlusion, which results in organ injury and pain.
The prognosis for children born with sickle cell disease has drastically changed
over the last three decades. In 1967 more than 50% of children with sickle cell disease
died before the age of 20 (9, 10). With the advent of newborn screening, pneumococcal
prophylaxis, and better comprehensive care, at least 90% of children born with sickle cell
disease now survive past their 20th birthday (8, 11). A study of 3764 patients with HbSS
disease published in the New England Journal of Medicine by Platt et al. in 1994 reported
a mean life expectancy of 42 years for males and 48 years for females with HbSS disease
(12). With more sickle cell disease patients surviving into adulthood, the frequency of
end organ complications has increased (11, 13). Thus, it is important to understand the
natural history of end organ dysfunction in children with sickle cell disease and develop
an approach to identifying children early who may be at increased risk of end organ
disease. With early identification and potential intervention, we may be able to decrease
the morbidity and mortality these children would face as adults.
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Elevated Tricuspid Regurgitant Jet Velocity
Pulmonary hypertension occurs in approximately one third of adults with sickle cell
disease and is associated with significantly increased morbidity and mortality (14, 15). A
clinical diagnosis of pulmonary hypertension can be hard to ascertain given the nonspecific symptoms, which include fatigue, shortness of breath, and increased heart rate.
The definitive diagnosis of pulmonary hypertension is made by right heart catheterization
with measurement of exact pulmonary artery pressures; however, this is an invasive and
expensive procedure with associated risks. Cardiac catheterization is therefore not a
suitable method for screening for pulmonary hypertension. Pulmonary artery systolic
pressures can be estimated by measurement of tricuspid regurgitant jet velocity (TRV) on
echocardiogram with the use of the modified Bernoulli equation (16). Without structural
obstruction to pulmonary blood flow, the right ventricular systolic pressure equals the
pulmonary artery systolic pressure. Studies have found that estimates of pulmonary
artery systolic pressure by Doppler echocardiography are well correlated with more
precise measures during cardiac catheterization (17, 18). The specificity of elevated TRV
to diagnose pulmonary hypertension increases as TRV increases. A recent study in a
small number of adults with sickle cell disease (N=25) found that the specificity of TRV
of 2.51 m/sec in diagnosing pulmonary hypertension was 18.8%, whereas with a TRV of
2.88 m/sec the specificity increased to 81% (19). Doppler echocardiography can thus be
used as a noninvasive way to identify patients who have or may be at risk for developing
pulmonary hypertension.
In adults with sickle cell disease, elevated TRV is the strongest predictor of
mortality versus other markers (20). The first study of TRV in adults with sickle cell
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disease was published in 1994 in a retrospective longitudinal analysis of 60 patients (21).
Over a mean follow up period of 22 months, the study found that mortality was
significantly greater in patients with pulmonary hypertension, defined in the study as
TRV !2.5 m/sec. Remarkably, 5 of 12 (42%) of the patients with pulmonary
hypertension died during the follow up versus only 4 of 48 (8%) of the patients without
pulmonary hypertension. The study found a statistically significant increase in mortality
in the patients with TRV !2.5 m/sec (P=0.03). In addition, multivariate analysis revealed
that elevated TRV was an independent predictor of death, whereas other variables
including older age, lower hematocrit, and cardiac symptoms were not independent
predictors of death (21). Furthermore, a prospective cross-sectional study published in
2004 by Gladwin and colleagues showed that elevated TRV (!2.5 m/s) had a prevalence
of 32%, and predicted approximately a ten-fold increased risk for early mortality in adults
with sickle cell disease (16).
Post mortem studies suggest that the pathological changes that result in pulmonary
hypertension in adults are chronic and may start during childhood (22-24). One study
published in 2001 by Adedeji and colleagues looked at pulmonary pathology in 12 sickle
cell patients at autopsy (23). The objective of the study was to investigate the potential
role that pulmonary embolism or small vessel arterial thrombosis play in the development
of pulmonary hypertension in sickle cell disease (23). The authors found that the most
common pulmonary findings were thrombotic arteriopathy of small pulmonary arteries,
which were present in 9 of the 12 patients. In all 9 patients they found right ventricular
hypertrophy, and in 8 of the 9 cases they found small arterial changes that were consistent
with pulmonary hypertension. The authors commented that it was possible the findings
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in the small arteries were from recurrent small pulmonary embolisms, but that the
histology of fresh thrombi likely showed sickled red blood cells within the fibrinous
developing clots (23). They concluded that there appears to be a progression from early
pulmonary alterations in childhood to obliterative vasculopathy in adults that is
irreversible.

Elevated TRV in Children With Sickle Cell Disease
Multiple pilot studies of children with sickle cell disease showed that they had a
similar prevalence of elevated TRV as adults. Studies in children report a 16–30%
prevalence of elevated TRV !2.5 m/sec on screening echocardiograms (25-27). Early
diagnosis of increased pulmonary artery pressures and treatment during childhood may
help to reverse these changes and reduce the morbidity and mortality correlated with
elevated TRV in adults with sickle cell disease. Further characterization of the natural
history and progression of TRV in children with sickle cell disease is critical to early
diagnosis and treatment.
A prospective study published in 2008 by Dr. Pashankar and colleagues found that
low oxygen saturation, high reticulocyte count, and high platelet count were significantly
associated with elevated TRV (25). While there have been multiple cross-sectional
studies, there have not been any studies to assess the natural history of TRV in children
with sickle cell disease followed longitudinally for many years. It is not known what
happens to patients with and without elevated TRV on baseline screening
echocardiogram over time. Studying the cohort of sickle cell children followed at Yale
offered us the ability to track TRV over time, and try to identify what potential factors
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place children at risk of having persistent elevation of TRV, or converting from normal to
elevated TRV over time. Longitudinal analysis of this patient population can help to
guide the timing of performing certain screening tests, and how to predict which children
may need to be closely monitored for the development of end organ dysfunction over
time.

Treatment of Elevated Tricuspid Regurgitant Jet Velocity
There is no effective treatment for adults with sickle cell disease who have
pulmonary hypertension, and it is thought to be irreversible (28, 29). Sildenafil, a
selective pulmonary vasodilator, was investigated in a double blind placebo controlled
study as a potential treatment for elevated TRV in adults with sickle cell disease.
Unfortunately, the trial was stopped early because of an increase in acute pain episodes in
the treatment group (35%) as compared to the placebo group (14%) (29). Other
treatments are currently being investigated, but there remain no FDA approved drugs for
adults with sickle cell disease related pulmonary hypertension. There have been limited
studies in children as to whether elevated TRV is potentially reversible with treatment. It
is possible that initiation of treatment earlier in the course of elevated TRV may be more
effective.
Hydroxyurea is the only FDA approved medication for the treatment of sickle cell
disease in the United States (30, 31). Hydroxyurea is used commonly to treat sickle cell
disease patients for indications including frequent vasooclusive crises, acute chest
syndrome, priapism, and severe anemia (30, 32, 33). Hydroxyurea treatment is thought
to be effective by increasing the amount of fetal hemoglobin, which then reduces red
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blood cell adhesion and decreases hemolysis (34-36).
In 2008, Dr. Pashankar and her team published a small pilot study, which assessed
the effect of hydroxyurea on elevated TRV in children with sickle cell disease. Five
patients who had persistent elevated TRV >2.5m/s were treated with hydroxyurea.
Echocardiograms were repeated every 6-12 months for a mean follow up of 24 months.
TRV decreased from 3.16±0.27 to 2.64±0.20 (P=0.017) after 3-6 months and to
2.42±0.26 mmHg (P=0.002) after 9-12 months on treatment (37). Based on these
preliminary findings, a prospective clinical trial was started at three centers including
Yale New Haven Children’s Hospital.

Pathogenesis and Study of Outcomes Associated with Elevated TRV
The exact pathogenesis of pulmonary hypertension is unknown and likely
multifactorial, with hemolysis induced nitric oxide depletion and vascular dysfunction
likely playing major role. Potential mechanisms for the development of pulmonary
hypertension include hypoxemia, repeated thrombotic embolism, iron overload, and
intravascular and parenchymal sequestering of red blood cells (16, 38-41). Recent
studies have highlighted the potential importance of inflammation in the pathogenesis of
pulmonary hypertension (42, 43).
Patients with sickle cell disease are at risk not only of pulmonary complications,
but dysfunction of other organs, as the disease is systemic and can impact any organ in
the body. Multiple studies tried to identify risk factors associated with elevated TRV in
children with sickle cell disease, though few have looked at clinical correlates or
outcomes associated with elevated TRV. The questions remain: are children with
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elevated TRV more likely to develop other end organ dysfunction? Do children with
elevated TRV, like their adult counterparts, have an increased mortality risk?

Sickle Cell Nephropathy
Like pulmonary hypertension, the development of sickle cell nephropathy is of
significant concern in adults with sickle cell disease. Renal failure affects approximately
12–21% of adults with sickle cell disease, and is associated with decreased survival (11,
44, 45). Approximately 25% of patients with sickle cell disease and end stage renal
disease die within the first year of starting dialysis (46). Renal involvement in sickle cell
disease is first characterized by a reversible urinary concentrating deficit, then a fixed
concentrating defect leading to polyuria (45, 47-49). Over time, glomerular hypertrophy
with a high GFR and increased renal blood flow leads to focal segmental
glomerulosclerosis, microalbinuria/proteinuria, hematuria, and ultimately renal failure in
many patients (45, 50-52).
One of the earliest manifestations of sickle cell nephropathy is microalbinuria/
proteinuria (53). The onset of proteinuria has been reported in early childhood, and
studies in children report a prevalence of microalbuminuria of 16-26% and a prevalence
of proteinuria of 6.2% (54-56). One study published in 2007 by McKie et al. in children
with sickle cell disease aged 3-20 reported that lower hemoglobin and older age were
significant associated with the presence of microalbinuria or proteinuria (54). The mean
hemoglobin with microalbuniria or proteinuria (N=37) was 7.71 g/dL versus 8.54 g/dL in
children without any urinary protein (N=154) (P=0.0004) (54). Additional risk factors
significantly associated with proteinuria in children with sickle cell disease reported from
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other studies include type of sickle cell disease, history of acute chest syndrome, and
stroke (55, 56).

Elevated TRV and Proteinuria
A study published in 2010 in adults with sickle cell disease found a positive
association between albuminuria and elevated TRV. The study reported that TRVs were
significantly higher (mean 3.15 m/s) in patients with macroalbuminuria (N=15) when
compared to patients with microalbuminuria or normalbuminuria (N=58) (mean 2.45
m/s) (P=0.00068) (57). Prior to our study, there was no data in children on the potential
association between kidney dysfunction manifested by proteinuria and elevated
pulmonary artery pressures as measured by TRV. We thus conducted our final study to
determine if elevated pulmonary artery systolic pressure, as estimated by
echocardiogram, was associated with proteinuria in children with sickle cell disease.
!
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PURPOSE
To determine the natural history of TRV in untreated children with sickle cell
disease, and to determine if elevated TRV is associated with proteinuria in children with
sickle cell disease.

HYPOTHESES
Untreated children with elevated TRV (!2.5 m/sec) will continue to be more likely to
have elevated TRV overtime. A proportion of children with sickle cell disease who
previously had normal TRV will go on to develop elevated TRV. Children with elevated
TRV are more likely to have or develop proteinuria.

SPECIFIC AIMS
1. To determine whether untreated children with elevated TRV (!2.5 m/sec) are likely
to have elevated TRV when followed longitudinally.
2. To determine what proportion of children with sickle cell disease who previously had
normal TRV will go on to develop elevated TRV, and what risk factors may be
associated.
3. To determine if elevated TRV is associated with proteinuria.
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METHODS

The author of this thesis was not involved in designing the yearly assessments,
which were conducted on children with sickle cell disease followed by the Yale New
Haven Hospital Pediatric Sickle Cell Program since 2005. The author did not collect the
primary data used for the studies, which was collected during clinic visits. Pediatric
Cardiologists were responsible for reading and interpreting the echocardiograms and
determining the TRV (if applicable). The author was responsible for abstracting primary
data from the paper and electronic medical records for each patient involved in the
studies, creating a de-identified database of all of clinical information, and performing all
statistical analysis completed as part of the studies. All aspects of the investigations were
supervised by Farzana Pashankar, MD.

1. Patient Population
The patient population for the two studies included children from the sickle cell
program at Yale New Haven Children’s Hospital, which follows children with sickle cell
disease in southern Connecticut. Patients in this program are seen at least annually for a
comprehensive assessment, during which a detailed clinical history, a complete physical
examination, and annual screening laboratory tests are performed. The clinical history
included documenting history of 1) acute chest syndrome 2) stroke 3) chronic blood
transfusions 4) treatment with hydroxyurea. The laboratory tests done during these visits
are those recommended by the American Academy of Pediatrics (58). The laboratory
tests included complete blood count, reticulocyte count, direct and total bilirubin levels,
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lactate dehydrogenase, serum urea nitrogen, creatinine level, and urinanalysis. Vital signs
were also measured during the visits including heart rate, blood pressure, respiratory rate,
and oxygen saturation by pulse oximetry. Transcranial Dopplers were performed on
patients with HbSS or S!° thalassemia between the ages of 2 and 14 years old as part of
screening for stroke. Starting in 2005, screening echocardiograms were conducted as part
of the annual comprehensive assessment for children older than 6 years with HbSS or S!°
thalassemia. Echocardiograms were performed as an outpatient visit at the Pediatric
Echocardiography Laboratory when patients were in a steady state, at least 2 weeks after
hospital admissions for vasoocclusive crises. The studies were approved by the
institutional review board (IRB) at Yale University School of Medicine.

2. Echocardiography
Two-dimensional Doppler echocardiography was performed for all patients using
the Philips IE33 ultrasound system (Philips Medical Systems, Bothell, WA) or the
Acuson Sequoia Ultrasound System (Siemens Medical Solutions, Malvern, PA).
Selection of appropriate transthoracic transducer was made during the evaluation.
Cardiac measurements were performed according to the guidelines of American Society
of Echocardiography. TRV was measured by pulsed-wave and continuous-wave Doppler
echocardiography where applicable. Multiple views (apical 4-chamber, parasternal short
axis, parasternal long axis) were obtained to record optimal tricuspid Doppler flow
signals, and a minimum of 5 sequential signals were recorded. The right ventricular to
right atrial systolic pressure gradient was calculated using the modified Bernoulli
equation (4 x V2). Pulmonary artery systolic pressure was quantified by adding the
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Bernoulli-derived right ventricular systolic peak pressure to the estimated mean right
atrial pressure (5 mm Hg). Pulmonary artery diastolic pressure was estimated by
measurement of the end diastolic velocity of the pulmonary insufficiency jet by similar
Doppler techniques. A peak TRV of 2.5 m/sec equating to a pulmonary artery pressure
of at least 30 mmHg was considered to be elevated. Peak TRV of 2.5 m/sec has been
previously used in studies of pulmonary hypertension in both adults and children with
sickle cell disease (16). Patients with no measurable TRV or TRV <2.5 m/sec were
considered to have normal pulmonary artery pressures, and these patients were
categorized as having normal TRV.

3. Study of the Natural History of TRV in Children with Sickle Cell Disease
For this study, charts including data from June 2005 to November 2012 were
reviewed. Patients with HbSS and S!° thalassemia who had screening echocardiograms
were included in the study. Patients with pulmonary stenosis or other structural
obstruction to pulmonary blood flow were excluded. Patients who were on chronic
transfusions or hydroxyurea prior to their first echocardiogram were included in the
study. Follow up echocardiogram data was censored for patients who started
hydroxyurea or chronic transfusions after their first screening echocardiogram. If a
patient subsequently stopped taking the medication, there echocardiograms continued to
be censored and were not included in the analysis. Data collected included baseline
demographics, type of sickle cell disease, clinical history, echocardiogram results, and
laboratory results. Longitudinal data from all subsequent echocardiograms were
collected. A database was created with de-identified data from each visit. The database
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included baseline clinical and laboratory data in addition to follow up echocardiograms
and treatment data (for example, dates of hydroxyurea treatment). For oxygen saturation
data, when there was a range, the average was taken (for example, O2 sat 90-92% was
recorded in the database as 91%). For echocardiogram data, when there was a range for
TRV, the lowest number was taken (for example, TRV 2.4-2.7 was recorded in the
database as 2.4). Data was analyzed using Chi square test for categorical variables and
student t-test for continuous variables. P value less than 0.05 was considered statistically
significant.

4. Study to Determine if Elevated TRV is Associated with Proteinuria
For this study, charts were reviewed from including data from June 2005 to July
2010. Patients who had a screening echocardiogram and a urinalysis within one year
were included in the study. Patients with pulmonary stenosis or other structural
obstruction to pulmonary blood flow were excluded. Baseline data collected included
demographics, type of sickle cell disease, clinical history, echocardiogram results,
laboratory results, and urinalysis. Urinalysis was sent for measurement of protein, which
was quantified from 0 to 3+. Urine protein 1+ equaled 30 mg/dl, 2+ equaled 100 mg/dl,
and 3+ equaled 300 mg/dl in our laboratory. Urine protein of 1+ to 3+ was considered
positive, urine protein of 0 was considered negative. Longitudinal data from all
subsequent echocardiograms and urinalyses for each subject were also collected. On
follow up, urinalysis was repeated at least annually. Echocardiograms were repeated
annually on patients with a baseline TRV !2.5 m/sec, and every two years on patients
with normal baseline TRV. Data was analyzed using Chi square test for categorical
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variables and student t-test for continuous variables. P value less than 0.05 was
considered statistically significant.
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RESULTS

Study 1. Natural history of TRV in Children with Sickle Cell Disease
Baseline Characteristics
A total of 100 patients aged 6-21 years were included, 87 with HbSS and 13 with
S!° thalassemia. The male to female ratio was 1.22:1. The mean age at initial screening
echocardiogram was 11.82 years (standard deviation was 4.16 years). On initial
screening echocardiograms, 67 of 100 patients (67%) had normal TRV <2.5 m/sec and 33
of 100 patients (33%) had elevated TRV !2.5 m/sec. Table I shows the baseline
characteristics of patients with and without elevated TRV on initial screening
echocardiogram (ECHO).
TABLE I. Characteristics of Patients With and Without TRV on Baseline Screening Echocardiogram
Baseline TRV
Patient Characteristics
Age at initial ECHO, mean ± SD, y
Male gender, n (%)
Genotype, n (%)
SS
S"°
H/O acute chest syndrome, n (%)
H/O stoke, n (%)
Hydroxyurea, n (%)
Blood transfusion, n (%)
Systolic BP, mean ± SD, mmHg
Oxygen saturation, mean ± SD
Hemoglobin, mean ± SD
Hematocrit, mean ± SD
Reticulocyte count, mean ± SD
WBC count (x10^3/µ), mean ± SD
Platelet count, mean ± SD
LDH, mean ± SD
Creatinine, mean ± SD, mg/dl
*P < 0.05.
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<2.5 m/sec
(n = 67)
11.60 ± 3.83
37 (55.22)

!2.5 m/sec
(n = 33)
12.33 ± 4.80
18 (54.55)

P value
0.21
0.88

55 (82.09)
12 (17.91)
23 (34.33)
9 (13.43)
15 (22.39)
11 (16.42)
108.37 ± 7.63
97.19 ± 2.38
8.70 ± 1.32
25.05 ± 4.30
10.09 ± 4.78
12.79 ± 5.04
414.78 ± 139.69
602.71 ± 245.43
0.51 ± 0.15

32 (96.97)
1 (3.03)
14 (42.42)
1 (3.03)
6 (18.18)
2 (6.06)
108.63 ± 8.91
95.83 ± 3.80
8.38 ± 1.01
23.43 ± 3.40
12.22 ± 5.66
12.48 ± 3.83
508.82 ± 140.76
637.50 ± 230.38
0.47 ± 0.16

0.57
0.20
0.82
0.25
0.44
0.01*
0.12
0.07
0.04*
0.38
0.001*
0.38
0.09

21
As shown in Table I, low daytime oxygen saturation, high reticulocyte count, and
high platelet count were significantly associated with elevated TRV (all P < 0.05). In the
group with elevated TRV, 32 of 33 (96.97%) of the patients had HbSS disease, whereas
only one of 33 (3.03%) of the patients had S"° thalassemia. In the group with normal
TRV, 12 of 67 patients (17.91%) had S"° thalassemia. History of acute chest syndrome
and history of stroke were not significantly different between patients with and without
elevated TRV. Similarly, other laboratory measures including hemoglobin, hematocrit,
white blood cell count, lactate dehydrogenase, and creatinine were not statistically
different between the two groups.
!
Longitudinal Follow Up of Echocardiograms
Repeat echocardiograms were available for 82% of patients (82 of 100) in the
study. The total follow up time was 283.23 years and the median follow up time per
patient was 3.59 years (range 0.11-7.32 years). The total number of repeat
echocardiograms was 230 with an average number of 2.80 follow up echocardiograms
per patient. As shown in Table II, 61.40% (N=35) of patients with baseline normal TRV
continued to have normal TRV on all subsequent echocardiograms, whereas 38.60%
(N=22) of patients had at least 1 echocardiogram with an elevated TRV. Follow up
echocardiograms were available for 25 of 33 patients (75.76%) with elevated TRV at
baseline. On follow up, 32% (N=8/25) of patients continued to have elevated TRV on all
subsequent echocardiograms, whereas 68% (N=17) of patients had at least 1
echocardiogram with normal TRV without intervention. Patients with a TRV !2.5 m/sec
on initial echocardiogram had a significantly higher chance of having repeat
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echocardiograms with elevated TRV compared to patients with normal baseline TRV
(P<0.0001). Patients with a TRV !2.5 m/sec on initial echocardiogram also had a
significantly higher chance of having persistent elevation of TRV on all follow up
echocardiograms (P=0.04).
TABLE II. Follow Up ECHOs in Patients With and Without Elevated TRV on Baseline Screening ECHO

Patient characteristics
Patients with follow up ECHO, n (%)
Total number of years
Average number of years per patient
Total number of ECHOs
Number of ECHOs per patient
Number of patients with TRV <2.5 m/sec on all repeat ECHOs (%)
Number of patients with TRV ! 2.5 m/sec on at least 1 repeat ECHO (%)
Number of patients with TRV ! 2.5 on all repeat ECHOs (%)
Number of repeat echocardiograms with TRV < 2.5 m/sec, n (%)
Number of repeat echocardiograms with TRV ! 2.5 m/sec, n (%)
*P < 0.05.

Baseline TRV
<2.5 m/sec
!2.5 m/sec
(n = 67)
(n = 33)
57 (85.07)
212.28
3.72
140
2.46
35 (61.40)
22 (38.60)
6 (10.53)
100 (71.4)
40 (28.6)

25 (75.76)
70.95
2.84
90
3.60
3 (12.00)
22 (88.00)
8 (32.00)
29 (32.2)
61 (67.8)

P value

<0.0001*
0.04*
<0.0001*

Based on the follow up echocardiogram data, patients were divided into four
groups. The objective of creating the four groups was to 1) determine potential factors
associated with TRV conversion from normal to elevated 2) identify potential factors
associated with persistent TRV elevation. The following were the four groups.
1) Patients with baseline TRV <2.5 m/sec who continued to have TRV <2.5 m/sec on
all repeat echocardiograms (N=35). This group was labeled Low-low.
2) Patients with baseline TRV <2.5 m/sec who had at least 1 repeat echocardiogram
with TRV >2.5 m/sec (N=22). This patient was labeled Low-high.
3) Patients with baseline TRV !2.5 m/sec who continued to have TRV !2.5 m/sec on
all repeat echocardiograms (N=8). This group was labeled High-high.
4) Patients with baseline TRV 2.5 m/sec who had at least 1 repeat echocardiogram
with TRV <2.5 m/sec (N=17). This group was labeled High-low.
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Table III shows the characteristics of the each of the four groups: Low-low, Lowhigh, High-high, High-low. Of note, 62.5% of the patients in the High-high group were
started on hydroxyurea after at least two echocardiograms with elevated TRV !2.5 m/sec.
Three patients died during the follow up period of the study, one in the low-low group
and two in the low-high group. All three patients had HbSS disease.

TABLE III. Characteristics of Four Longitudinal Follow Up Groups

Total number of ECHOs
Average number of ECHOs per patient
Total number of years
Average number of years per patient
Number of ECHOs <2.5
Number of ECHOs !2.5
# patients with 1 ECHO >2.5
# patients with 2 ECHO >2.5
# patients with 3 ECHO >2.5
# patients with 4 ECHO >2.5
# patients with 5 ECHO >2.5
# patients started on HU during study
# patients deceased during study
% of patients started on HU

Low-low
(N = 35)

Low-High
(N = 22)

High-high
(N = 8)

High-low
(N = 17)

94
2.69
108.57
3.10
94
0
0
0
0
0
0
9
1
25.71%

103
4.68
103.71
4.71
63
40
11
7
2
1
1
1
2
4.55%

24
3.00
12.73
1.59
0
24
0
4
2
3
0
5
0
62.5%

66
3.88
58.22
3.42
29
37
4
7
5
1
0
3
0
17.65%

As shown in Table IV and Table V, baseline factors including clinical and
laboratory data were examined for differences between the Low-low group and Low-high
group to determine risk factors for TRV conversion. Baseline factors were also examined
between the High-high group and the High-low group to determine factors associated
with persistent elevation of TRV. Significant risk factors associated with TRV
conversion from normal to elevated were baseline low O2 saturation, and high
reticulocyte count (all P <0.05). High white blood cell count was trending towards a
significance as a risk factor associated with TRV conversion (P=0.07).
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TABLE IV. Risk Factors Associated with TRV Conversion
Low-low
Baseline Characteristics
(N = 35)
TRV, mean ± SD
2.20 ± 0.17
Age, mean ± SD
11.87 ± 3.67

Low-high
( N = 22)
2.27 ± 0.16
11.32 ± 4.05

P value
0.09
0.30

O2 Saturation, mean ± SD
Hemoglobin, mean ± SD
Reticulocyte count, mean ± SD

97.71 ± 2.33
8.80 ± 1.42
8.47 ± 3.66

95.86 ± 2.59
7.89 ± 1.07
13.61 ± 4.88

0.004*
0.12
0.0001*

12.26 ± 5.64
401.29 ± 119.39

14.47 ± 4.60
438.05 ± 178.63

WBC count (x10^3/µ), mean ± SD
Platelet count, mean ± SD
*P < 0.05.

0.07
0.18

As shown in Table V, significant risk factors associated with persistent TRV elevation
were baseline TRV, hemoglobin, and white blood cell count (all P <0.05). Lower oxygen
saturation was trending towards significance as a factor associated with persistent TRV
elevation (P=0.06)
TABLE V. Risk Factors Associated with Persistent TRV Elevation
High-high
High-low
Baseline Characteristics
(N = 8)
(N = 17)
TRV, mean ± SD
2.79 ± 0.15
2.63 ± 0.15
Age, mean ± SD
14.58 ± 5.13
12.07 ± 4.04
O2 Saturation, mean ± SD
94.43 ± 4.79
96.91 ± 2.65
Hemoglobin, mean ± SD
7.79 ± 1.01
8.83 ± 0.93
Reticulocyte count, mean ± SD
11.91 ± 2.41
10.39 ± 3.94
WBC count (x10^3/µ), mean ± SD
14.96 ± 4.83
11.66 ± 3.26
Platelet count, mean ± SD
545.38 ± 212.97
489.47 ± 130.16
*P < 0.05.

!

P value
0.02*
0.09
0.06
0.009*
0.18
0.03*
0.21
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Study 2. Is Elevated TRV Associated with Proteinuria in Children with Sickle Cell
Disease?
Baseline Characteristics
A total of 85 patients aged 6–21 years were included in the study. The baseline
characteristics were similar to the Study 1. Seventy-two patients had HbSS disease and
13 patients had S!° thalassemia. The male to female ratio was 1.36:1. The mean age at
initial screening echocardiogram was 12.16 years (standard deviation was 4.15 years).
On initial screening echocardiograms, 28 of 85 patients (32.9%) had elevated TRV !2.5
m/sec. Table VI shows the baseline characteristics of patients with and without elevated
TRV. As shown in Table I, low daytime oxygen saturation, high reticulocyte count, and
high platelet count were significantly associated with elevated TRV. Of the 28 patients
with elevated TRV, 2 patients (7.14%) had proteinuria compared to 1 of 57 patients
(1.75%) with normal TRV. This was not a statistically significant finding (P=0.25).
TABLE VI. Characteristics of Patients With and Without High TRV on Baseline Screening ECHO
Baseline TRV
Patient characteristics
Age at echocardiogram, mean ± SD, y
Male gender, n (%)
Genotype, n (%)
SS
S"°
H/O acute chest syndrome, n (%)
Hydroxyurea, n (%)
Blood transfusion, n (%)
Stroke/abnormal TCD, n (%)
Systolic BP, mean ± SD, mmHg
Oxygen saturation, mean ± SD
Hemoglobin, mean ± SD, g/L
Hematocrit, mean ± SD
Reticulocyte count, mean ± SD
WBC count (x103/ml), mean ± SD
Platelet count, mean ± SD
LDH, mean ± SD
Total bilirubin, mean ± SD
Creatinine, mean ± SD, mg/dl
Positive urine protein, n (%)
*P < 0.05.

!

<2.5 m/sec
(n = 57)

!2.5 m/sec
(n = 28)

11.72 ± 3.93
33 (57.89)

13.04 ± 4.45
16 (57.14)

45 (78.9)
12 (21.0)
23 (40.3)
12 (21.0)
12 (21.0)
10 (7.5)
108.42 ± 8.10
97.28 ± 2.45
8.45 ± 1.30
24.49 ± 4.13
10.43 ± 5.39
14.23 ± 5.34
406.48 ± 143.08
648.21 ± 254.30
3.25 ± 2.50
0.52 ± 0.16
1 (1.75)

27 (96.43)
1(3.57)
16 (57.14)
5 (17.86)
2 (7.14)
1 (3.57)
110.00 ± 7.63
95.56 ± 4.46
8.30 ± 1.09
23.11 ± 3.50
13.66 ± 6.73
13.53 ± 4.76
505.39 ± 143.75
650.50 ± 255.18
3.90 ± 2.51
0.48 ± 0.16
2 (7.14)

P value
0.17
0.86
0.22
0.15
0.78
0.12
0.09
0.39
0.02*
0.60
0.13
0.040
0.55
0.003*
0.98
0.30
0.25
0.25
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Longitudinal Follow Up of Echocardiograms and Urinalysis
As shown in Table VII, when patients were grouped based on their initial screening
echocardiograms, follow up urinalysis data was available in 92.86% of patients with
elevated TRV and in 94.73% of patients with normal TRV. The number of follow up
urinalysis per patient was 6.17 in the high TRV group and 7.24 in the normal TRV group.
Of the 173 repeat urine analyses in patients with elevated TRV, 19.08% were positive for
proteinuria (P=0.04).
TABLE VII. Follow Up Urinalysis in Patients With and Without High TRV on Baseline Screening ECHO
Baseline TRV
Patient characteristics
Patients with follow up urinalysis, n (%)
Total number of urinalysis
Number of urinalysis per patient
Number of urinalysis with positive protein, n (%)
*P < 0.05.

<2.5 m/sec
(n = 57)

!2.5 m/sec
(n = 28)

54 (94.73%)
413
7.24
51 (12.35%)

26 (92.86%
173
6.17
33 (19.08)

P value

0.04*

As shown in Table VIII, when patients were grouped based on the presence of any
echocardiogram (baseline or follow up) having TRV !2.5 m/sec, follow up urinalysis
were available in 95.35% of patients with elevated TRV and 92.86% of patients with
normal TRV. Of the 302 repeat urinalysis in patients with any elevated TRV, 21.52%
were positive for proteinuria compared to 6.69% (19 of 284 urine samples) in patients
with every TRV < 2.5 m/sec (P=<0.001).
TABLE VIII. Follow Up Urinalysis in Patients With and Without High TRV on Any ECHO (Baseline or
Follow Up)

Patient characteristics
Patients with follow up urinalysis, n (%)
Total number of urinalysis
Number of urinalysis per patient
Number of urinalysis with positive protein, n (%)
*P < 0.05.

!

Baseline TRV
<2.5 m/sec
!2.5 m/sec
(n = 42)
(n = 43)
39 (92.86%)
284
7.28
19 (6.69)

41 (95.35%)
302
7.36
65 (21.52)

P value

<0.001*
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DISCUSSION

Our first study showed that on initial screening echocardiogram 33% of patients
had elevated TRV !2.5 m/sec. Risk factors associated with increased TRV were similar
to the study previously published by Dr. Pashankar and her group at Yale and included
low daytime oxygen saturation, high reticulocyte count, and high platelet count, all of
which are signs of increased hemolysis (25). Other studies in have shown a similar
association between low daytime oxygen saturation and elevated TRV (27, 59). It is
unclear whether hypoxia plays a direct role in the development of increased TRV in
children with sickle cell disease. Chronic hypoxia from multiple conditions predisposes
patients to the development of pulmonary hypertension (60). These conditions include
chronic obstructive pulmonary disease, pulmonary fibrosis, sleep-disordered breathing,
and exposure to high altitude. In children with sickle cell disease and elevated TRV,
hypoxia may play a direct role in the development of increased pulmonary artery
pressures, as has been suggested in previous studies (27). Alternatively, the relationship
between low oxygen saturation and elevated TRV may not be a causative one. Low
oxygen saturation may indicate that these are patients with higher rates of hemolysis, who
are therefore predisposed to the development of elevated TRV. This indirect relationship
is supported by the association between elevated TRV and other markers of hemolysis,
including high reticulocyte and high platelet count.
Over a median follow up time of 3.59 years, 61% of patients with normal TRV at
baseline continued to have normal TRV, indicating that most patients who have normal
TRV will continue to have normal TRV. On follow up, there were a significant
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proportion of patients, almost 40%, who had a normal baseline TRV, but subsequently
had an elevated TRV !2.5 m/sec. Interestingly, this group of patients was distinct in
terms of other clinical measures from their counterparts who remained with normal TRV
over time. Risk factors associated with TRV conversion were baseline low oxygen
saturation and high reticulocyte count (all P <0.05). These are similar to the risk factors
that put patients at increased risk of having elevated TRV at screening and suggest that
patients who have laboratory or clinical markers of increased hemolysis may need to be
monitored more closely and may need to have screening echocardiograms on an annual
basis. The finding that low oxygen saturation was a risk factor for TRV conversion again
highlights the importance of monitoring children with lower oxygen saturation closely.
Patients with normal TRV and no signs of increased hemolysis (low oxygen saturation,
high reticulocyte count) can likely be screened with echocardiograms every 2 years, as
opposed to annually, which is currently the suggested practice at the Yale Sickle Cell
Program.
For the 33% of patients with elevated TRV at baseline, follow up was available
for 75.76% (25 of 33) of the patients. There were ten patients who were started on
hydroxyurea treatment after one echocardiogram with elevated TRV, and this
substantially affected the follow up data available for this cohort. On follow up of the
children with elevated TRV at baseline 32% (N=8/25) of patients continued to have
elevated TRV on all subsequent echocardiograms, whereas 68% (N=17) of patients had
at least 1 echocardiogram with normal TRV without intervention. This finding highlights
that the reproducibility of TRV measurement is limited. This was was previously shown
by the Dr. Pashankar and other investigators (37, 61). It is therefore important to repeat
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echocardiograms and ensure that the elevated TRV is persistent before considering any
therapeutic intervention. Notably, despite the small patient size, significant risk factors
associated with persistent TRV elevation were baseline TRV, hemoglobin, and white
blood count.
In adults with sickle cell disease elevated TRV is associated with multiple
important clinical outcomes, of which the most notable is increased mortality (16, 62). In
addition, studies in adults with sickle cell disease with elevated TRV have found
significant associations with pulmonary hypertension, decreased exercise capacity (Sixminute walk test), leg ulcers ,and proteinuria (13, 16, 29, 63-66). There have been
limited studies in children with elevated TRV to investigate associations with clinical
outcomes. Sickle cell disease children with increased TRV do not appear to have the
same increased risk of short-term mortality that adults with elevated TRV have.
Two studies in children with sickle cell disease have looked at the clinical
associations with elevated TRV. One study published in 2009 in a cohort of children and
adolescents with sickle cell disease (N=230) found that patients with elevated TRV had a
decline in oxygen saturation during exercise with the six-minute walk test (P=0.0002)
(27). Unlike in adults, the study did not find an association between elevated TRV and
decreased exercise tolerance as measured with the six-minute walk test (27). Another
study published in 2011 on children aged 3-20 years old found that over a median follow
up of 22 months, baseline TRV elevation was associated with a 4.4-fold increase in the
odds of a 10% or more decline in exercise tolerance (P=0.015). Our study is the first to
examine whether there is an association between elevated TRV and proteinuria in
children with sickle cell disease.
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In our second study, urine protein was present in 2 (7.14%) patients with TRV !2.5
m/sec compared to 1 (1.75%) patient with normal TRV. This was not statistically
significant, due to the small numbers in each group. Interestingly, the patient with
normal TRV who had proteinuria at baseline did have a borderline high TRV of 2.4–2.7
m/sec on initial echocardiogram. All of his subsequent echocardiograms showed a high
TRV >3 m/sec, hence it is likely that the pulmonary artery pressures were evolving at the
time of the initial echocardiogram.
Follow up of urinalysis data showed a significant association between proteinuria
and elevated TRV when patients were grouped either based on their initial
echocardiogram or on any subsequent echocardiogram showing TRV !2.5 m/sec. A
positive association between proteinuria and pulmonary hypertension has been reported
previously in adults (13, 57). Ours is the first study showing that proteinuria is associated
with elevated TRV in children with sickle cell disease.
The underlying potential pathogenesis linking proteinuria and elevated pulmonary
artery systolic pressures is unclear at this time. Both complications occur in childhood
with increasing prevalence with age (54, 55, 67, 68). Both complications are risk factors
for death in sickle cell disease patients (12, 16). The risk factors for elevated pulmonary
artery pressures are markers of hemolysis such as low hemoglobin, elevated reticulocyte
count, elevated lactate dehydrogenase, and high hemolytic index. The pathogenesis of
elevated pulmonary artery pressures is thought to be multifactorial with hemolysis
induced nitric oxide depletion and consequent vascular dysfunction playing a major role.
Recently the role of inflammation has been described in the pathogenesis.
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Albuminuria is common in sickle cell disease patients and is reported in 16–26%
of children. Studies in adults with sickle cell disease report a 42% prevalence of
albuminuria. Risk factors associated with albuminuria include older age, type of sickle
cell disease, history of acute chest syndrome, and serum creatinine (37, 55). The
association of low hemoglobin with albuminuria or proteinuria has varied in different
reports. Several investigators showed that albuminuria/proteinuria was associated with
low hemoglobin (54, 57, 69, 70). Others have not found an association between low
hemoglobin and albuminuria (55, 57, 68). However Ataga et al. did find that hemoglobin
levels were lower and lactate dehydrogenase levels were higher in patients with
macroalbuminuria compared to patients with microalbuminuria or normoalbuminuria,
hence postulating that hemolysis may play a role in albuminuria in sickle cell disease
(57). Interestingly, they also found that the levels of sFLT-1, soluble VCAM, and NT
pro-BNP were significantly higher in patients with macroalbuminuria as compared to
patients with microalbuminuria or normoalbuminuria. sFLT-1, a tyrosine kinase protein
which inhibits VEGF, has also been shown to be associated with PHT. The association
between albuminuria and elevated pulmonary artery systolic pressures may be in part due
to endothelial activation and endothelial dysfunction that is known to follow increased
levels of sFLT-1.
Our study of the association between elevated TRV and proteinuria has some
limitations. The data was collected retrospectively and in some patients the
echocardiograms and urinalysis were not performed simultaneously. There were some
missing urinalysis and echocardiogram data points. Additionally, due to the nature of the
available data we were only able to examine proteinuria, and were not able to quantify
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microabinuria in the patient population that we studied. The addition of microalbinuria
data may have strengthened or further revealed important information about the potential
association between elevated TRV and urinary protein. Therefore, we recommend that a
prospective study be conducted, ideally on a larger patient population across multiple
clinical sites to further define this association and potentially examine the role of
microalbinuria in addition to fulminant proteinuria.
In conclusion, our second study shows that elevated TRV is associated with
proteinuria in children with sickle cell disease. The underlying pathogenesis linking the
two conditions is currently being explored. It is likely that hemolysis or inflammation
induced endothelial dysfunction may play a role.
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Proteinuria is Associated With Elevated Tricuspid Regurgitant Jet Velocity in
Children With Sickle Cell Disease
Suzanne Forrest, BA,1 Ashley Kim,2 Judith Carbonella, APRN,1 and Farzana Pashankar, MD1*
Background. Sickle cell disease (SCD) affects multiple organ
systems. Complications of SCD such as pulmonary hypertension
(PHT) and sickle cell nephropathy (SCN) are associated with an
increased mortality. Both PHT and SCN have some common risk
factors. In adults, PHT has been found to be associated with albuminuria, a manifestation of SCN. There is no data on this association in children. We conducted a study to determine if elevated
pulmonary artery systolic pressures estimated on echocardiogram
was associated with proteinuria in children with SCD. Methods.
A detailed retrospective chart review was conducted on a cohort
of sickle cell patients screened with echocardiograms from
June 2005 to July 2010. Patients who had an initial screening
echocardiogram and urine analysis within 1 year were included.
Longitudinal data from all subsequent echocardiograms and urine

Key words:

analyses were collected. Results. Eighty-five patients were included.
On initial echocardiograms 32.9% had an elevated tricuspid regurgitant jet velocity (TRV) !2.5 m/second. On follow up, in the 28
patients with elevated TRV, 49.27% of all repeat echocardiograms
showed persistent elevation. In the 57 patients with normal baseline
TRV, 73.6% of all repeat echocardiograms continued to have normal TRV. On initial screening 7.14% of patients with elevated TRV
had proteinuria compared to 1.75% without elevated TRV. On
follow up, 19.08% of repeat urinalysis had proteinuria in patients
with elevated baseline TRV compared to 12.35% in patients with
normal baseline TRV (P ¼ 0.04). Conclusions. Elevated TRV !
2.5 m/second is significantly associated with proteinuria on longitudinal follow up in children with SCD. Pediatr Blood Cancer
2012;58:937–940. ! 2011 Wiley Periodicals, Inc.

children; proteinuria; pulmonary hypertension; sickle cell disease

INTRODUCTION
Pulmonary hypertension (PHT) occurs in approximately one
third of adults with sickle cell disease (SCD) and is associated
with a significantly increased mortality [1–3]. The definitive
diagnosis of PHT is made by right heart catheterization, however
this is invasive. Pulmonary artery systolic pressures can be estimated by measurement of tricuspid regurgitant jet velocity (TRV)
on echocardiogram. Studies in children report a 16–30% prevalence of elevated TRV ! 2.5 m/second on screening echocardiograms [4–6]. The pathogenesis of PHT is likely multifactorial
and several investigators have proposed that hemolysis induced
nitric oxide depletion and vascular dysfunction play a major role
[3,7–10]. More recent reports highlight the role of inflammation
in the pathogenesis of PHT [11,12].
Sickle cell nephropathy (SCN) is of significant concern in
adults with SCD and renal failure affects 12–21% of adults
with SCD [13,14]. One of the early manifestations of SCN is
proteinuria. The onset of proteinuria has been reported in early
childhood, and studies in children report a 16–26% prevalence of
microalbuminuria and a 6.2% prevalence of proteinuria [15–18].
Risk factors associated with albuminuria in children include older
age, low hemoglobin, history of acute chest syndrome (ACS), and
type of SCD. Recently a study in adults found a positive association between albuminuria and PHT [19]. However, there are no
data in children on the potential association between kidney dysfunction manifested by proteinuria and elevated pulmonary artery
pressures. We hence conducted a study to determine if elevated
pulmonary artery systolic pressures estimated on echocardiograms was associated with proteinuria in children with SCD.

vaso-occlusive crises. TRV was measured by pulsed-wave and
continuous wave Doppler echocardiography. Multiple views
(apical four chamber, parasternal short axis, parasternal long
axis) were obtained to record optimal tricuspid Doppler flow
signals and a minimum of five sequential signals were recorded.
A peak TRV of !2.5 m/second equating to a pulmonary artery
pressure of at least 30 mmHg was considered to be elevated.
Other evaluations done during the visit included a detailed history,
complete physical examination and laboratory studies including
complete blood count, reticulocyte count, renal and liver function
tests and urinalysis. Urinalysis was sent for measurement of protein, which was quantified from 0 to 3þ. Urine protein 1þ
equaled 30 mg/dl, 2þ equaled 100 mg/dl, and 3þ equaled
!300 mg/dl in our laboratory. Urine protein of 1þ to 3þ was
considered positive, urine protein of 0 was considered negative.
On follow up, urinalysis was repeated at least annually. Echocardiograms were repeated annually on patients with a baseline
TRV ! 2.5 m/second, and every 2 years on patients with normal
baseline TRV.
For this study, charts were reviewed from June 2005 to
July 2010. Patients who had a screening echocardiogram and a
urinalysis within 1 year were included in the study. Baseline data
collected included demographics, type of SCD, clinical history,
echocardiogram results, laboratory results, and urinalysis. Longitudinal data from all subsequent echocardiograms and urinalyses
for each subject were also collected. Data were analyzed using
Chi square test for categorical variables and t-test for continuous
variables. The study was approved by the institutional review
board.

METHODS
1

A detailed retrospective chart review was conducted on a
cohort of SCD patients. Starting in June 2005, screening echocardiograms were incorporated at our center as part of the annual
evaluation of children with Hb SS and Hb Sb0 thalassemia older
than 6 years of age. Screening echocardiograms were done when
patients were in steady state, at least 2 weeks after admission for
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TABLE I. Characteristics of Patients With and Without TRV on Baseline Screening Echocardiogram
Baseline TRV
Patient characteristics
Age at echocardiogram, mean # SD, y
Male gender, n (%)
Genotype, n (%)
SS
Sb0
H/O acute chest syndrome, n (%)
Hydroxyurea, n (%)
Blood transfusion, n (%)
Stroke/abnormal TCD, n (%)
Systolic BP, mean # SD, mmHg
Oxygen saturation, mean # SD
Hemoglobin, mean # SD, g/L
Hematocrit, mean # SD
Reticulocyte count, mean # SD
WBC count (%103/ml), mean # SD
Platelet count, mean # SD
LDH, mean # SD
Total bilirubin, mean # SD
Creatinine, mean # SD, mg/dl
Positive urine protein, n (%)
$

<2.5 m/second
(n ¼ 57)

>2.5 m/second
(n ¼ 28)

11.72 # 3.93
33 (57.89)

13.04 # 4.45
16 (57.14)

45 (78.9)
12 (21.0)
23 (40.3)
12 (21.0)
12 (21.0)
10 (7.5)
108.42 # 8.10
97.28 # 2.45
8.45 # 1.30
24.49 # 4.13
10.43 # 5.39
14.23 # 5.34
406.48 # 143.08
648.21 # 254.30
3.25 # 2.50
0.52 # 0.16
1 (1.75)

27 (96.43)
1(3.57)
16 (57.14)
5 (17.86)
2 (7.14)
1 (3.57)
110.00 # 7.63
95.56 # 4.46
8.30 # 1.09
23.11 # 3.50
13.66 # 6.73
13.53 # 4.76
505.39 # 143.75
650.50 # 255.18
3.90 # 2.51
0.48 # 0.16
2 (7.14)

P
0.17
0.86

0.22
0.15
0.78
0.12
0.09
0.39
0.02$
0.60
0.13
0.04$
0.55
0.003$
0.98
0.30
0.33
0.25

P < 0.05.

RESULTS
A total of 85 patients aged 6–21 years were included in the
study. Seventy-two patients had Hb SS disease and 13 patients
had Sb0 thalassemia. The male to female ratio was 1.36:1. The
mean age at initial screening echocardiogram was 12.16 years
with a SD 4.15 years. On initial screening echocardiograms, 28
of 85 patients (32.9%) had TRV ! 2.5 m/second. Table I shows
the baseline characteristics of patients with and without elevated
TRV. As shown in Table I, low daytime oxygen saturation, high
reticulocyte count, and high platelet count were significantly
associated with elevated TRV. Of the 28 patients with elevated
TRV, 2 patients (7.14%) had proteinuria compared to 1 of 57
patients (1.75%) with normal TRV.
Follow up data was available for 82 patients. Average follow
up time was 3.23 years (range 0.27–5.15 years). As shown in
Table II, 89.29% of patients with elevated TRV had repeat
echocardiograms compared to 86% of patients with normal

TRV. The number of follow up echocardiograms per patient was
2.76 in the high TRV group and 2.24 in the normal TRV group. In
the 28 patients with baseline high TRV, 49.27% of the repeat
echocardiograms (N ¼ 69) showed persistent elevation of
TRV ! 2.5 m/second. In the 57 patients with baseline TRV <
2.5 m/second, 73.6% of all repeat echocardiograms (N ¼ 110)
continued to have TRV < 2.5 m/second. Patients with a
TRV ! 2.5 m/second on initial echocardiogram had a significantly higher chance of having repeat echocardiograms with
elevated TRV compared to patients with normal baseline TRV
(P ¼ 0.003).
As shown in Table III, when patients were grouped based on
their initial screening echocardiograms, follow up urinalysis data
was available in 92.86% of patients with elevated TRV and in
94.73% of patients with normal TRV. The number of follow up
urinalysis per patient was 6.17 in the high TRV group and 7.24 in
the normal TRV group. Of the 173 repeat urine analyses in
patients with elevated TRV, 19.08% were positive for proteinuria

TABLE II. Follow Up Echocardiograms in Patients With and Without Elevated TRV on Baseline Screening ECHO
Baseline TRV
Patients characteristics
Patients with follow-up ECHO, n (%)
Total number of echocardiograms
Number of echocardiograms per patient
Number of patients with repeat echocardiograms
showing TRV >2.5 m/second (%)
Number of repeat echocardiograms with TRV >2.5 m/second, n (%)
Number of repeat echocardiograms with TRV <2.5 m/second, n (%)
$

P < 0.05.
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<2.5 (n ¼ 57)

>2.5 (n ¼ 28)

P

49 (85.96%)
110
2.24
15 (30.6%)

25 (89.29%)
69
2.76
15 (60%)

0.029$

29 (26.36%)
81 (73.6%)

34 (49.27%)
35 (50.7%)

0.003$
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TABLE III. Follow Up Urinalysis in Patients With and Without Elevated TRV on Baseline Screening ECHO
Baseline TRV
Patients characteristics

<2.5 (n ¼ 57)

>2.5 (n ¼ 28)

54 (94.73%)
413
7.24
51 (12.35%)

26 (92.86%)
173
6.17
33 (19.08%)

Patients with follow-up urinalysis, n (%)
Total number of urinalysis
Number of urinalysis per patient
Number of urinalysis with positive protein, n (%)
#

P

0.04#

P < 0.05.

compared to 12.35% (51 of 413 urine samples) in patients with
normal baseline TRV (P ¼ 0.04).
As shown in Table IV, when patients were grouped based on
the presence of any echocardiogram (baseline or follow up) having TRV " 2.5 m/second, follow up urinalysis were available in
95.35% of patients with elevated TRV and 92.86% of patients
with normal TRV. Of the 302 repeat urinalysis in patients with
any elevated TRV, 21.52% were positive for proteinuria compared
to 6.69% (19 of 284 urine samples) in patients with every
TRV < 2.5 m/second (P ¼ <0.001).

DISCUSSION
Our study shows that on initial screening echocardiogram
32.9% of patients had an elevated TRV " 2.5 m/second. Risk
factors associated with increased TRV were similar to our previous study [4] and included low daytime oxygen saturation, high
reticulocyte count, and high platelet count. Other studies have
shown a similar association between low daytime oxygen saturation and elevated TRV [6,20]. Urine protein was present in 2
(7.14%) patients with TRV " 2.5 m/second compared to 1
(1.75%) patient with normal TRV. This was not statistically significant, due to the small numbers in each group. Interestingly, the
patient with normal TRV who had proteinuria at baseline did have
a borderline high TRV of 2.4–2.7 m/second on initial echocardiogram. All of his subsequent echocardiograms showed a high
TRV > 3 m/second, hence it is likely that the pulmonary artery
pressures were evolving at the time of the initial echocardiogram.
On follow up, we found that patients with normal TRV at
baseline had a 73.6% likelihood of continuing to have normal
TRV on subsequent echocardiograms. In patients with baseline
elevated TRV, 49.27% of repeat echocardiograms showed persistent elevation, while 50.7% of repeat echocardiograms were normal with TRV < 2.5 m/second. This observation highlights that
the reproducibility of TRV measurement is limited. This has been
previously shown by us and other investigators [21,22]. It is hence
important to repeat echocardiograms and ensure that the elevated
TRV is persistent before considering any intervention.

Follow up of urinalysis data showed a significant association
between proteinuria and elevated TRV, when patients were
grouped either based on their initial echocardiogram or on any
subsequent echocardiogram showing TRV " 2.5 m/second. A
positive association between proteinuria and PHT has been
reported previously in adults [19,23]. Ours is the first study showing that proteinuria is associated with elevated TRV in children
with SCD.
The underlying potential pathogenesis linking proteinuria and
elevated pulmonary artery systolic pressures is unclear at present.
Both complications occur in childhood with increasing prevalence
with age [15–17,24]. Both complications are risk factors for death
in SCD patients [3,25]. The risk factors for elevated pulmonary
artery pressures are markers of hemolysis such as low hemoglobin, elevated reticulocyte count, elevated LDH, and high hemolytic index. The pathogenesis of elevated pulmonary artery
pressures is thought to be multifactorial with hemolysis induced
nitric oxide depletion and consequent vascular dysfunction playing a major role. Recently the role of inflammation has been
described in the pathogenesis.
Albuminuria is common in SCD patients and is reported in
16–26% of children with SCD. Studies in adults with SCD report
a 42% prevalence of albuminuria. Risk factors associated with
albuminuria include older age, type of SCD, history of ACS, and
serum creatinine [16,21]. The association of low hemoglobin with
albuminuria or proteinuria has varied in different reports. Several
investigators showed that albuminuria/proteinuria was associated
with low hemoglobin [15,18,26,27]. Others have not found
an association between low hemoglobin and albuminuria
[16,19,24]. However Ataga et al. [19] did find that hemoglobin
levels were lower and lactate dehydrogenase levels were higher
in patients with macroalbuminuria compared to patients with
microalbuminuria or normoalbuminuria, hence postulating that
hemolysis may play a role in albuminuria in SCD. Interestingly,
they also found that the levels of s FLT-1, soluble VCAM, and NT
pro-BNP were significantly higher in patients with macroalbuminuria as compared to patients with microalbuminuria or
normoalbuminuria. s FLT-1 has also been shown to be associated

TABLE IV. Follow Up Urinalysis in Patients With and Without Elevated TRV on Any ECHO (Baseline or Follow Up)
Baseline TRV
Patients characteristics
Patients with follow-up urinalysis, n (%)
Total number of urinalysis
Number of urinalysis per patient
Number of urinalysis with positive protein, n (%)
#

P < 0.05.
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<2.5 (n ¼ 42)

>2.5 (n ¼ 43)

39 (92.86%)
284
7.28
19 (6.69%)

41 (95.35%)
302
7.36
65 (21.52%)

P

<0.001#

940

Forrest et al.

with PHT [28]. The association between albuminuria and elevated
pulmonary artery systolic pressures may be in part due to endothelial activation and endothelial dysfunction that follow
increased levels of s FLT-1.
Our study has some limitations. The data were collected
retrospectively and in some patients the echocardiograms and
urinalysis were not performed simultaneously. There were some
missing urinalysis and echocardiogram data points. We hence
recommend doing a prospective study to further define this
association.
In conclusion, our study shows that elevated TRV is associated
with proteinuria in children with SCD. The underlying pathogenesis linking the two conditions is currently being explored and it
is likely that hemolysis or inflammation induced endothelial
dysfunction may play a role.
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HIGHLIGHT

by Gregory J. Kato, MD*y

TRV: A Physiological Biomarker in Sickle Cell Disease
(Commentary on Forrest et al., page 937)

C

linical and translational research makes the biggest leaps
in human disease when effective biomarkers are developed
and put into play. Effective biomarkers are often convenient
surrogate markers of clinical outcomes that dramatically speed
up the development of clinically useful interventions. They also
often point to new mechanistic pathways that open up opportunities for new intervention strategies. The biomarkers may be
biochemical, physiological, imaging, or any other reproducible
indicator. Familiar examples of effective biomarkers that guide
clinical management resulting in improved clinical outcomes
include blood pressure, serum cholesterol, or tumor size from
radiographic imaging.
In sickle cell disease (SCD), the first truly successful biomarker was fetal hemoglobin [1]. Natural history epidemiological
investigation demonstrated that patients with higher levels suffer
fewer clinical complications of SCD. Bench investigations
showed that fetal hemoglobin inhibited polymerization of sickle
hemoglobin. Intervention with hydroxyurea raises fetal hemoglobin levels, and improves clinical outcomes. Hydroxyurea is now
an approved, standard of care drug in SCD, and indications for its
prescription continue to expand.
The second truly successful biomarker in SCD is a physiological biomarker: transcranial Doppler (TCD) velocity of blood flow
in the cerebral arteries [2]. TCD velocity predicts risk of stroke in
children with SCD. Therapeutic intervention with monthly transfusion of red blood cells lowers the TCD velocity, and markedly
reduces the incidence of first stroke. Three very important lessons
emerged from TCD research. Successful application of TCD: (i)
occurred despite lack of consensus over the precise physiological
mechanism of TCD velocity; (ii) occurred despite known limitations in its specificity; (iii) required highly standardized TCD
measurement conditions and specific technician training.
In this issue of Pediatric Blood & Cancer, Forrest et al. at Yale
University show that tricuspid regurgitant velocity (TRV) measured during Doppler echocardiography in children with SCD is a
biomarker that associates with proteinuria, a sign of renal disease.
In order to put this observation in perspective, it is helpful to trace
the findings that establish TRV as a physiological biomarker in
SCD.
Elevated TRV predicts mortality in adults with SCD more
strongly than any other marker. A longstanding marker of pulmonary hypertension in the echocardiography world, TRV was first
introduced as a biomarker in SCD research by Sutton et al. [3] in
a retrospective study. Gladwin et al. [4] published a prospective
cross-sectional screening study of adults with SCD that showed
that a TRV of two standard deviations above the mean
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(!2.5 m/second) was prevalent (32%), and predicted about a
10-fold risk for early mortality [4], findings confirmed by Ataga
et al. [5]. Both Gladwin and Ataga attributed the findings to
pulmonary hypertension, correct in principle. However, since
the consensus clinical definition of pulmonary hypertension uses
a threshold for diagnosis of mean pulmonary artery pressure three
standard deviations above the mean (25 mmHg) by right heart
catheterization, these differences in definitions have led to confusion and debate [6]. Nevertheless, TRV is emerging as a robust
physiological biomarker of clinical outcome in SCD.
TRV in SCD adults reproducibly correlates with several important clinical outcomes. Several studies confirm that elevated
TRV in SCD adults is associated with important clinical
outcomes: pulmonary hypertension [7–9], proteinuria [10,11],
leg ulcers [4,7,12–15], decreased exercise capacity [8,16], and
early death [4,5]. TRV is one of several longstanding noninvasive
modalities for estimating pulmonary artery pressure in the fields
of echocardiography and pulmonary hypertension. This same association has been documented by right heart catheterization
studies in SCD [8]. In adults, TRV !2.5 m/second has a positive
predictive value for pulmonary hypertension of only 25% [7],
although addition of NT-proBNP to the screening criteria may
help provide, respectable yields for a screening test. TRV can be a
useful screening tool in adults with SCD, especially if coupled
with a 6-minute walk distance <500 m [16,17].
To put these numbers in context, TCD velocity is highly useful
and now constitutes standard of care despite an estimated positive
predictive value of only 36% [18]. Like TRV, (i) there is lack of
consensus over the precise physiological mechanism of TCD
velocity [6]; (ii) there are limitations in its specificity; (iii) highly
standardized measurement conditions are required to minimize
variability [19].
It would be ideal to identify subjects at high risk to target
preventative strategies. Elevated TRV is detectable in childhood
[20], decades before the typical age at which pulmonary hypertension becomes clinically symptomatic [21]. Elevated TRV in
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children with SCD is associated with many of the same clinical
features found in SCD adults with elevated TRV: higher systolic
blood pressure, lower hemoglobin, higher serum levels of bilirubin, and lactate dehydrogenase [20]. SCD children with elevated
TRV show a greater decline in systemic arterial oxygen saturation
during exercise than children without a TRV elevation [22].
Although it is not immediately associated with decreased exercise
capacity as it is in adults with SCD, elevated TRV in children with
SCD predicts future loss of exercise capacity [23].
Forrest et al. in this issue add another piece to this picture,
showing that abnormal TRV in children with SCD is associated
with proteinuria, a form of end organ disease seen also in SCD
adults with high TRV [10,11]. It appears at this point that childhood echocardiography screening might be identifying an early
stage of elevated TRV, but only long-term longitudinal cohort
studies will give the definitive answer. These children over years
or decades may be at risk to develop loss of exercise capacity and
potentially clinically significant pulmonary hypertension. More
research is needed in order to provide better evidence regarding
screening guidelines in children with SCD.
Children with SCD and elevated TRV may be an ideal group
for randomized controlled trials to test possible strategies to prevent progression to high-risk status in adulthood. Such trials
might test hydroxyurea or other disease modifying strategies for
this indication. Since death with high TRV appears to occur
mainly in adulthood, such trials would need to use a more immediate surrogate marker, such as exercise capacity, an endpoint
accepted by the Food and Drug Administration for approval of
pulmonary hypertension therapeutics. If and when an intervention
in presymptomatic children with high TRV is found that prevents
progression to adulthood pulmonary hypertension and death, TRV
will have fully followed in the footsteps of TCD as a physiological biomarker of risk in children with SCD.
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